Clopidogrel use | N | Cases | Crude rate | Unadjusted hazard ratio |
p* | Adjusted hazard ratio |
p* |
|---|
HR (95% CI) | HR (95% CI) |
|---|
9 months
| | | | | | | |
Discontinuous | 292 | 61 | 20.9% | 1.00 (Reference) | | 1.00 (Reference) | |
Continuous | 452 | 66 | 14.6% | 0.70 (0.49-0.99) | 0.04 | 0.69 (0.48-1.00) *
| 0.05 |
12 months
| | | | | | | |
Discontinuous | 382 | 53 | 13.9% | 1.00 (Reference) | | 1.00 (Reference) | |
Continuous | 317 | 29 | 9.2% | 0.66 (0.42-1.04) | 0.07 | 0.59 (0.36-0.95) † | 0.03 |
15 months
| | | | | | | |
Discontinuous | 489 | 45 | 9.2% | 1.00 (Reference) | | 1.00 (Reference) | |
Continuous | 164 | 13 | 7.9% | 0.84 (0.45-1.56) | 0.58 | 0.57 (0.29-1.13) ‡ | 0.11 |
- HR = hazard ratio, CI = confidence interval.
-
*Adjusted for comorbidities (hypertension, DM uncontrolled, myocardial infarction), use of aspirin, multivessel PCI, number of stents, at least 1 DES, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
- † Adjusted for comorbidities ( hypertension, DM uncontrolled, GI bleeding/ulcer, myocardial infarction) , use of aspirin, NSAID, multivessel PCI, number of stents, at least 1 DES, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
- ‡ Adjusted for age, comorbidities (hypertension, DM uncontrolled, GI bleeding/ulcer, peripheral vascular disease, myocardial infarction), use of aspirin, NSAID, multivessel PCI, number of stents, at least 1 DES, total stent length > 45 mm, minimum of stent diameter < 2.5 mm, ostium lesion, bifurcation lesion, LM lesion.
